Ukraine and Russia Execute Major 270-Person Prisoner Swap; Bristol-Myers Reports Breakthrough Breast Cancer Data

By / / Breaking News

This update was written automatically with AI from market data and news wire reports, and published without review by a person.

Key Takeaways

  • Bristol-Myers Squibb (BMY) announced that its investigational drug iza-bren reduced the risk of disease progression or death by 59% in a Phase 3 breast cancer study, significantly outperforming standard chemotherapy.
  • Ukraine and Russia completed a major prisoner exchange involving 540 total servicemen, with each side returning 270 people following successful negotiations.
  • The iza-bren clinical results showed a median progression-free survival (PFS) of 8.2 months compared to 4.0 months for the chemotherapy control group.
  • Ukrainian President Volodymyr Zelenskyy confirmed the return of 270 Ukrainians, many of whom were defenders of Mariupol and had been in captivity since 2022.
  • BMY shares rose over 3% in early trading as investors reacted to the late-breaking data presented at the ESMO 2026 Congress.

Bristol-Myers Squibb Unveils Superior Phase 3 Breast Cancer Results

Bristol-Myers Squibb (BMY) and partner SystImmune reported groundbreaking results from the Phase 3 PANKU-Breast01 trial at the European Society for Medical Oncology (ESMO) 2026 Congress. The study evaluated izalontamab brengitecan (iza-bren), a first-in-class dual-targeting bispecific antibody-drug conjugate (ADC), in patients with advanced HR+/HER2- breast cancer.

The trial met its primary endpoint with a 59% reduction in the risk of disease progression or death. The confirmed objective response rate (cORR) for patients receiving iza-bren was 40.5%, doubling the 20.2% response rate observed in the chemotherapy arm. Additionally, the median duration of response (mDOR) was extended to 6.9 months from the 4.2 months seen with standard care.

Market analysts noted that the safety profile remained manageable, with only 1.6% of patients discontinuing treatment due to adverse events. These results position iza-bren as a potential new standard of care for patients who have failed prior lines of endocrine therapy and chemotherapy.

Ukraine and Russia Conduct Large-Scale Prisoner Exchange

In a significant humanitarian development, Ukraine and Russia exchanged 270 prisoners of war each on Friday, October 23. President Volodymyr Zelenskyy announced the successful return of Ukrainian service members, including personnel from the National Guard, Azov unit, and Border Guards.

The swap, mediated through ongoing diplomatic channels, also saw the return of nine Ukrainian civilians. Notably, five of the returned individuals were previously believed to have died during the 2022 attack on the Olenivka prison. This exchange marks the 11th reported swap of 2026, highlighting a rare but consistent area of cooperation between the two warring nations.

The Russian Defense Ministry confirmed that its 270 returned servicemen were transported to Belarus for medical and psychological rehabilitation. While broader peace negotiations remain stalled, officials from both sides indicated that further exchanges of civilians and military personnel are expected to continue in the coming days.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top